Company intelligence / Profile preview

ATLAB Pharma

Nantes, France

Ownership: Private
Development stage: Other

Overview

Phase II trial of ATL101 (Lutetium-177 anti-PSMA antibody) in 47 mCRPC patients showed 47% PSA decline >30%, reduced circulating tumor cells, and median overall survival of 21.8 months at 70 mCi/m² dose; well-tolerated with transient hematologic effects.[2]

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Biotech

Beyond the preview

Go deeper on ATLAB Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATLAB Pharma.

Explore the full profile